Shares of Cellectar Biosciences Inc. (CLRB) are soaring over 34% in pre-market today, after the biopharmaceutical company announced that the U.S. FDA has granted Fast Track Designation for CLR 131 in lymphoplasmacytic lymphoma or LPL/Waldenstrom's macroglobulinemia or WM in patients having received two prior treatment regimens or more.
from RTT - Before the Bell https://ift.tt/2B3ouol
via IFTTT
No comments:
Post a Comment